

# EXECUTIVE SUMMARY

Full Year 2025




## Main figures €Mn

<b>Op. Revenue</b>	<b>EBITDA</b>	<b>EBIT</b>
<b>743.5 (-3%)</b>	<b>216.2 (+4%)</b>	<b>185.8 (+4%)</b>
<b>Net profit</b>	<b>Capex</b>	<b>Net debt</b>
<b>140.4 (+3%)</b>	<b>67.8 (+9%)</b>	<b>21.9</b>


**2026 operating revenue growth rate:**  
Increase by between a high single-digit and low double-digit percentage vs 2025

- ✓ ROVI announces a collaboration with Roche for the manufacture of a new medicine in development.
- ✓ Acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA). As part of the transaction, ROIS signed a 5-year Toll Manufacturing Agreement with BMS.
- ✓ Final Decision to award aid of €36.3 Mn for ROVI's LAISOLID project subsidised by the CDTI.
- ✓ ROVI acquires a majority position in Cells IA Technologies, S.L.

## Operating revenue €Mn



## Specialty pharma business €Mn




## CDMO<sup>(1)</sup> business €Mn




(\*) "Other operating income" includes service activities that are not material to the Group.  
<sup>(1)</sup> Contract Development and Manufacturing Organisation  
 To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRS, please consult the information included on this subject on page 1 and Appendix 2 (pages 35-39) of the press release on the financial results for the full year 2025. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>

## Gross profit €Mn




■ Gross profit — Gross margin

## SG&A expenses €Mn



■ SG&A — SG&A/Operating revenue

## EBITDA €Mn



■ EBITDA — EBITDA Margin

## R&D expenses €Mn €37.8

+47%


Product	Potential Indication	Current Situation	Key Milestones
Risperidone ISM®, monthly	<b>Schizophrenia</b>	Approved	Marketed in Europe, and in Australia & Taiwan
Letrozole ISM®, annual	<b>Breast Cancer</b>	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole SIE <sup>(1)</sup> , quarterly	<b>Breast Cancer</b>	Completion of phase I	Phase I: positive readout confirms superior estrogen suppression vs Femara® and allows progression to phase III clinical trial
Risperidone ISM®, quarterly	<b>Schizophrenia</b>	Completion of phase I	Phase I: positive readout allows progression to phase III clinical trial

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile  
Multiple FDA / GMP approved facilities to support the platform

(1) Superior Inhibition of Estrogen  
To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 35-39) of the press release on the financial results for the full year 2025. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>



## Net profit €Mn



(1) Calculated excluding R&D expenses in 2025 and 2024

## News flow

### SPECIALTY PHARMA

Additional new products to be launched

Granting by the competent local authorities of the marketing authorisation of an Enoxaparin biosimilar outside Europe

### CDMO

Production progress of key manufacturing agreements

ROIS Phoenix

### ISM® Technology Platform

Marketing of Okedj® in Europe and rest of the world

Phase III clinical trial of a three-monthly formulation of letrozole (Letrozole SIE)

Phase III clinical trial of risperidone for a 3-monthly injection